1. Bioprospection of Antiviral and Antitumor Compounds from Some Marine Algae from Egyptian Shores. Ahmed, E.M., A.A. Hamdy, and B.M. Alshehri. Anti-cancer Agents in Medicinal Chemistry, 2022. 22(9): p. 1813-1825. PMID[34431468].
[PubMed]. HBV_07_2022.
2. A Carrier-free Metal-organic Hybrid Nanoassembly with Combination Anti-viral and Hepato-protective Activity for Hepatitis B Treatment. Dong, H., X. Hong, Y. He, Z. Bao, Y. Zhang, S. Shen, G. Wang, J. Zhang, and R. Mo. Biomaterials Science, 2022. 10(15): p. 4356-4366. PMID[35786722].
[PubMed]. HBV_07_2022.
3. A Small Molecule Targeting Hepatitis B Surface Antigen Inhibits Clinically Relevant Drug-resistant Hepatitis B Virus. Kiruthika, S., R. Bhat, B. Jayaram, and P. Vivekanandan. Journal of Antimicrobial Chemotherapy, 2022. 77(8): p. 2120-2124. PMID[35514268].
[PubMed]. HBV_07_2022.
4. Entry Inhibition of Hepatitis B Virus Using Cyclosporin O Derivatives with Peptoid Side Chain Incorporation. Lee, D., J.A. Kang, C. Lim, S. Bae, J. Choi, M. Park, Y.C. Kim, Y. Cho, S.G. Park, and J. Seo. Bioorganic and Medicinal Chemistry, 2022. 68: 116862. PMID[35691131].
[PubMed]. HBV_07_2022.
5. Psoralen Inhibits Hepatitis B Viral Replication by Down-regulating the Host Transcriptional Machinery of Viral Promoters. Ma, X., H. Li, Y. Gong, F. Liu, X. Tong, F. Zhu, X. Yang, L. Yang, and J. Zuo. Virologica Sinica, 2022. 37(2): p. 256-265. PMID[35305922]. PMCID[PMC9170971].
[PubMed]. HBV_07_2022.
6. Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-Hepatitis B Virus Compound. Tan, S., E. Groaz, R. Kalkeri, R. Ptak, B.E. Korba, and P. Herdewijn. Journal of Medicinal Chemistry, 2022. 65(13): p. 9396-9417. PMID[35754374].
[PubMed]. HBV_07_2022.
7. Cyclocytidine hydrochloride Inhibits the Synthesis of Relaxed Circular DNA of Hepatitis B Virus. Wang, X., Y. Xiao, Z. Cui, Z. Li, L. Li, L. Wu, F. Yin, and X. Cui. PeerJ, 2022. 10: e13719. PMID[35846878]. PMCID[PMC9285472].
[PubMed]. HBV_07_2022.
8. Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir. Won, J., A.R. Lee, M. Dezhbord, D.R. Lee, S.H. Kim, J.C. Kim, S. Park, N. Kim, B. Jae, and K.H. Kim. Biomedicines, 2022. 10(7): 1637. PMID[35884942]. PMCID[PMC9312910].
[PubMed]. HBV_07_2022.
9. An O-Benzyl phosphonamidate Prodrug of Tenofovir for the Treatment of Hepatitis B Virus Infection. Zhang, Q., Y. Peng, J. Hou, Y. Chen, B. Liu, P. Zhang, W. Yu, and J. Chang. Journal of Medicinal Chemistry, 2022. 65(13): p. 9493-9505. PMID[35776695].
[PubMed]. HBV_07_2022.
Patent Citations
10. Synergistic Effect of Farnesoid X Receptor (FXR) Agonists and Interferon Alpha (Ifn-Α) for the Treatment of Hepatitis B Virus (HBV) Infection. Darteil, R., P. Scalfaro, J. Vonderscher, E. Roy, and D. Durantel. Patent. 2022. 2022-EP50589 2022152770: 33pp.
[Patent]. HBV_07_2022.
11. Dihydropyrimidine Derivatives and Uses Thereof in the Treatment of HBV Infection or of HBV-induced Diseases.Jiang, Y., Z. Cheng, G. Deng, Z. Liu, C. Liang, J. Wu, L. Kong, X. Deng, and Y. Xu. Patent. 2022. 2022-CN74479 2022161448: 279pp.
[Patent]. HBV_07_2022.